TherapeuticsMD (NASDAQ:TXMD – Get Free Report) and GSK (NYSE:GSK – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Valuation and Earnings
This table compares TherapeuticsMD and GSK”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TherapeuticsMD | $3.27 million | 7.29 | -$570,000.00 | $0.02 | 103.00 |
| GSK | $33.20 billion | 2.83 | $7.54 billion | $3.20 | 14.53 |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for TherapeuticsMD and GSK, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
| GSK | 3 | 12 | 4 | 0 | 2.05 |
GSK has a consensus price target of $55.33, suggesting a potential upside of 19.01%. Given GSK’s stronger consensus rating and higher possible upside, analysts plainly believe GSK is more favorable than TherapeuticsMD.
Risk and Volatility
TherapeuticsMD has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
Profitability
This table compares TherapeuticsMD and GSK’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
| GSK | 14.56% | 43.23% | 11.60% |
Institutional & Insider Ownership
30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
GSK beats TherapeuticsMD on 10 of the 14 factors compared between the two stocks.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
